Alembic Pharmaceuticals shareholding pattern

Who owns itSep 2026 quarter

Promoters69.87%no change
Foreign investors (FII)4.55%+0.37 pts
Domestic institutions (DII)15.43%−0.51 pts
of which mutual funds8.50%−0.23 pts
of which insurance companies6.46%
Public10.15%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹15,623 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group69.6169.6169.6169.6769.6769.7469.7469.7469.8769.87
FII / FPI4.323.944.173.943.964.054.244.254.184.55
DII15.4716.0516.0616.4316.4616.3016.1716.1815.9415.43
Mutual Funds8.058.908.969.209.058.558.228.188.738.50
Latest: 2026-09-30 · 63 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.